Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials

Abstract Background The benefit of adding Zolbetuximab to the treatment in patients with Claudin-18 isoform 2 (CLDN18.2)-positive, human epidermal growth factor receptor 2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJ) is not yet...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Francisco Cezar Aquino de Moraes, Eric Pasqualotto, Matheus Pedrotti Chavez, Rafael Oliva Morgado Ferreira, Tiago Biachi De Castria, Rommel Mario Rodríguez Burbano
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2024-02-01
סדרה:	BMC Cancer
נושאים:	Claudin-18 isoform 2 Zolbetuximab Gastric adenocarcinoma Adenocarcinoma of the gastro-oesophageal junction Oesophageal adenocarcinoma
גישה מקוונת:	https://doi.org/10.1186/s12885-024-11980-w
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!